Biostage, Inc. entered into securities purchase agreements with certain investors in a private placement an aggregate of 1,000,967 common shares at a price of $6 per share for the gross proceeds of $6.005802 million on March 31, 2023.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | +3.02% | +3.02% | -52.10% |
1st Jan change | Capi. | |
---|---|---|
-52.10% | 34.21M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. announced that it expects to receive $6.005802 million in funding